stockrow
Saturday 7 November 2026
Export QTTB’s income statement to Excel — free account
Q32 Bio Inc.
QTTB Healthcare Biotechnology
Q32 Bio Inc.’s revenue for fiscal 2025 (year ended December 2025) was $53.7 million.
- EPS
- +43.6%
- Free cash flow
- +71.1%
- Total debt
- −35.6%
Quarter to June 2026, against a year earlier
9.25
0.40
+4.52%
Follow QTTB
Alert me
Q32 Bio Inc. (QTTB) P/E ratio
As of 6 November 2026, Q32 Bio Inc. (QTTB) trades at a P/E ratio of 3.1×. Over the past ten years it has ranged from 0.0× (December 2025) to 7.1× (July 2026); the current reading is higher than 96% of that period. That is below the Biotechnology industry median of 10.6× and below the Healthcare sector median of 24.5×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 1.4× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Dec 2023 | 0.0× | — |
| Sep 2023 | 0.0× | — |
| Jun 2023 | 0.0× | — |
| Mar 2023 | 0.0× | — |
| 20 more quarters | Free account |
Against its own ten years
Low 0.0×
High 7.1×
Ten-year median
0.0×
Current reading's percentile
96
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| TTRX Turn Therapeutics Inc. compare | n/m |
| SPRY ARS Pharmaceuticals, Inc. compare | n/m |
| SABS SAB Biotherapeutics, Inc. compare | n/m |
| NAUT Nautilus Biotechnology, Inc. compare | n/m |
| RCKT Rocket Pharmaceuticals, Inc. compare | n/m |
| ARCT Arcturus Therapeutics Holdings Inc. compare | n/m |
| IPSC Century Therapeutics, Inc. compare | n/m |
| QTTB Q32 Bio Inc. | 3.1× |
| VOGX Vogenx Inc compare | — |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)